NASDAQ:SILK - Silk Road Medical Stock Price, Forecast & News

Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."

Silk Road Medical Inc (NASDAQ:SILK) issued its quarterly earnings data on Tuesday, October, 29th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.27) by $0.01. The business earned $17 million during the quarter, compared to analyst estimates of $15.93 million. The company's revenue was up 77.1% on a year-over-year basis. View Silk Road Medical's Earnings History.

Silk Road Medical is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Silk Road Medical.

Silk Road Medical will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

5 analysts have issued 1 year price targets for Silk Road Medical's shares. Their forecasts range from $40.01 to $52.00. On average, they anticipate Silk Road Medical's share price to reach $44.80 in the next twelve months. This suggests that the stock has a possible downside of 4.6%. View Analyst Price Targets for Silk Road Medical.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Silk Road Medical.

Media coverage about SILK stock has trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Silk Road Medical earned a news impact score of -1.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Silk Road Medical.

Silk Road Medical saw a decline in short interest in January. As of January 31st, there was short interest totalling 1,220,000 shares, a decline of 6.2% from the January 15th total of 1,300,000 shares. Based on an average trading volume of 331,100 shares, the short-interest ratio is presently 3.7 days. Currently, 6.0% of the shares of the stock are short sold. View Silk Road Medical's Current Options Chain.

Some companies that are related to Silk Road Medical include Globus Medical (GMED), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), ICU Medical (ICUI), Nevro (NVRO), NuVasive (NUVA), Cantel Medical (CMD), Glaukos (GKOS), Irhythm Technologies (IRTC), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP), AtriCure (ATRC), Cardiovascular Systems (CSII), Atrion (ATRI) and Tactile Systems Technology (TCMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include Alibaba Group (BABA), Splunk (SPLK), Cisco Systems (CSCO), salesforce.com (CRM), CVS Health (CVS), Home Depot (HD), Thermo Fisher Scientific (TMO), DexCom (DXCM), Workday (WDAY) and Abbott Laboratories (ABT).

(SILK) raised $75 million in an initial public offering on Thursday, April 4th 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Silk Road Medical's stock is owned by a number of of retail and institutional investors. Top institutional investors include Warburg Pincus LLC (19.13%), Janus Henderson Group PLC (6.25%), Alliancebernstein L.P. (4.73%), Bamco Inc. NY (4.41%), Jennison Associates LLC (3.97%) and Victory Capital Management Inc. (2.48%). Company insiders that own Silk Road Medical stock include Andrew S Davis, Erica J Rogers, Lucas W Buchanan, Pincus & Co Warburg, Richard Ruedy and X Finance LP Wp. View Institutional Ownership Trends for Silk Road Medical.

SILK stock was sold by a variety of institutional investors in the last quarter, including Warburg Pincus LLC, Janus Henderson Group PLC, Lord Abbett & CO. LLC, Schonfeld Strategic Advisors LLC, Credit Suisse AG, Nicholas Investment Partners LP, ArrowMark Colorado Holdings LLC and Advisor Group Inc.. Company insiders that have sold Silk Road Medical company stock in the last year include Andrew S Davis, Erica J Rogers, Lucas W Buchanan, Pincus & Co Warburg, Richard Ruedy and X Finance LP Wp. View Insider Buying and Selling for Silk Road Medical.

SILK stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Alliancebernstein L.P., Cannell Peter B & Co. Inc., Parkman Healthcare Partners LLC, Jennison Associates LLC, Sectoral Asset Management Inc, Bamco Inc. NY and Massachusetts Financial Services Co. MA. View Insider Buying and Selling for Silk Road Medical.

Shares of SILK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SILK stock can currently be purchased for approximately $46.95.

Silk Road Medical has a market capitalization of $1.45 billion and generates $34.56 million in revenue each year. Silk Road Medical employs 176 workers across the globe.View Additional Information About Silk Road Medical.

The official website for Silk Road Medical is http://silkroadmed.com/.

Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The company can be reached via phone at 408-720-9002 or via email at [email protected]